Glucotrack announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. Ballantyne brings over 20 years of experience on the executive team at the global biotechnology contract development and manufacturing organization, Aldevron. He co-founded the company in 1998 and served as its Chief Science Officer through its acquisition by Danaher, and until his retirement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GCTK:
- JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
- GlucoTrack Welcomes New VP of Clinical Operations
- GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS
- GlucoTrack appoints Sandie Martha as VP, clinical operations
- GlucoTrack Shares Market Research Insights Publicly